The ability of osteoclasts to resorb bone relies on a well defined sequence of events starting with their attachment to matrix. This binding is mediated to a significant degree, by the integrin alphavbeta3 and thus, regulation of the heterodimer's expression on the cell surface represents a logical approach to controlling the resorptive process. We find that retinoic acid, a member of the steroid hormone superfamily which enhances bone resorption in vivo and in vitro, increases steady state levels of beta3-integrin mRNA and expression of alphavbeta3 on the surface of avian osteoclast precursors. We hypothesize that: 1) retinoic acid enhances steady state beta3 mRNA levels by retinoic acid receptor-mediated transcriptional activation; 2) retinoic acid enhances alphavbeta3 surface expression on osteoclast precursors by selective synthesis to the beta3 subunit; and 3) retinoic acid-stimulated alphavbeta3 surface expression by their precursors enhances the capacity of the osteoclasts to attach to matrix and ultimately resorb bone. To explore these hypotheses, we propose to: 1) Characterize the regulatory elements responding to retinoic acid in the beta3 gene and their interaction with retinoic acid receptor. 2) Determine the effects of retinoic acid on both synthesis and degradation of alphav and beta3 by osteoclast precursors. 3) Examine the effects of osteoclast precursor treatment with retinoic acid on the ability of mature osteoclasts to attach to matrix and resorb bone.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Research Project (R01)
Project #
5R01AR042404-02
Application #
2081626
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Project Start
1993-05-01
Project End
1996-04-30
Budget Start
1994-05-01
Budget End
1995-04-30
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Barnes-Jewish Hospital
Department
Type
DUNS #
City
Saint Louis
State
MO
Country
United States
Zip Code
63110
Feng, Xu; Takeshita, Sunao; Namba, Noriyuki et al. (2002) Tyrosines 559 and 807 in the cytoplasmic tail of the macrophage colony-stimulating factor receptor play distinct roles in osteoclast differentiation and function. Endocrinology 143:4868-74
Wei, S; Teitelbaum, S L; Wang, M W et al. (2001) Receptor activator of nuclear factor-kappa b ligand activates nuclear factor-kappa b in osteoclast precursors. Endocrinology 142:1290-5
Srivastava, S; Toraldo, G; Weitzmann, M N et al. (2001) Estrogen decreases osteoclast formation by down-regulating receptor activator of NF-kappa B ligand (RANKL)-induced JNK activation. J Biol Chem 276:8836-40
Feng, X; Novack, D V; Faccio, R et al. (2001) A Glanzmann's mutation in beta 3 integrin specifically impairs osteoclast function. J Clin Invest 107:1137-44
McHugh, K P; Kitazawa, S; Teitelbaum, S L et al. (2001) Cloning and characterization of the murine beta(3) integrin gene promoter: identification of an interleukin-4 responsive element and regulation by STAT-6. J Cell Biochem 81:320-32
Legler, D F; Wiedle, G; Ross, F P et al. (2001) Superactivation of integrin alphavbeta3 by low antagonist concentrations. J Cell Sci 114:1545-53
Lai, C F; Feng, X; Nishimura, R et al. (2000) Transforming growth factor-beta up-regulates the beta 5 integrin subunit expression via Sp1 and Smad signaling. J Biol Chem 275:36400-6
Cheng, S L; Lai, C F; Fausto, A et al. (2000) Regulation of alphaVbeta3 and alphaVbeta5 integrins by dexamethasone in normal human osteoblastic cells. J Cell Biochem 77:265-76
Abu-Amer, Y; Erdmann, J; Alexopoulou, L et al. (2000) Tumor necrosis factor receptors types 1 and 2 differentially regulate osteoclastogenesis. J Biol Chem 275:27307-10
Inoue, M; Ross, F P; Erdmann, J M et al. (2000) Tumor necrosis factor alpha regulates alpha(v)beta5 integrin expression by osteoclast precursors in vitro and in vivo. Endocrinology 141:284-90

Showing the most recent 10 out of 27 publications